Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AtriCure's improved tissue ablator:

This article was originally published in Clinica

Executive Summary

The US FDA has given AtriCure 510(k) marketing clearance to use its Isolator Synergy bipolar ablation system on soft tissue. The device is a next generation version of the firm's FDA-cleared Isolator bipolar ablation system; neither product has yet been cleared for cardiac use or for treating atrial fibrillation. It incorporates two pulsing pairs of electrodes in the jaws of the clamp to create a uniform, full-thickness ablation lesion shaped like a column, which the West Chester, Ohio firm believes will result in more durable ablation lines in thicker and more diseased tissues. The company anticipates launching a minimally-invasive version of the device during the third quarter of 2007.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047563

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel